Studying brain lymphoma with advanced genetic testing
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This study collects and analyzes tumor samples from people diagnosed with a type of brain lymphoma to learn more about the disease and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older).
- You have a diagnosis of primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) between 2018 and 2024.
- Your tumor sample is stored in a tissue bank (FFPE).
- You do not have a weakened immune system.
- Your lymphoma did not start elsewhere in the body and spread to the brain, and it is not a transformed lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses brain biopsy and spinal fluid (lumbar puncture) tests to better diagnose and understand how well treatments may work for certain lymphomas in the brain. It may help doctors match the right therapy by studying what the disease looks like in the body and brain.
This trial looks at the immune system and metabolism of people with primary central nervous system lymphoma (a type of brain cancer) to find differences that might help with future treatments. It does not test a new drug, but collects samples and medical information.
This study looks at how primary central nervous system (CNS) lymphoma can be identified and tracked using scans and molecular (tissue/biomarker) tests. It may help doctors better understand your disease and choose the best next steps.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This study collects blood, cerebrospinal fluid, and tumor tissue samples over time from people with suspected or confirmed primary central nervous system lymphoma (PCNSL) in China. The goal is to build a large biobank to better understand the disease and improve future diagnosis and treatment.
Hear when a new Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.